You just read:

Surveyed U.S. Oncologists Indicate That if Iressa and Tomtovok Were Approved for Treating NSCLC Patients With EGFR Mutations, Both Agents Would Threaten Tarceva's Market Position in This Niche Population

News provided by

Decision Resources

Dec 02, 2010, 08:00 EST